Cargando…

The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset

BACKGROUND: Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanfang, Li, Yongguo, Jiang, Wenhui, Li, Qian, Lan, Yinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456118/
https://www.ncbi.nlm.nih.gov/pubmed/30921182
http://dx.doi.org/10.1097/MD.0000000000014810
_version_ 1783409709828538368
author Zhang, Yanfang
Li, Yongguo
Jiang, Wenhui
Li, Qian
Lan, Yinghua
author_facet Zhang, Yanfang
Li, Yongguo
Jiang, Wenhui
Li, Qian
Lan, Yinghua
author_sort Zhang, Yanfang
collection PubMed
description BACKGROUND: Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the prognosis of patients with HCC based on all eligible literatures. METHODS: Numerous electronic databases (MEDLINE, Embase, Pubmed, Google Scholar, and China Biology Medicine disc) were applied to retrieve relevant studies. Overall survival (OS) and progression-free survival (PFS) were used as primary endpoints. All statistical analyses were performed by RevMan software version 5.3.5 and STATA software version 14.1. In addition, the results of this meta-analysis were validated by an independent dataset from the Cancer Genome Atlas (TCGA). RESULTS: A total of 11 studies containing 1124 patients were included in this meta-analysis. The pooled results showed that low miR-122 expression in HCC tissues significantly associated with unfavorable OS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] 1.22–1.80, P < .001) and PFS (HR = 1.54, 95% CI 1.28–1.85, P < .001) in patients with HCC. However, the expression level of miR-122 in blood did not have the ability in predicting OS (HR = 0.75, 95% CI 0.44–1.28, P = .29) and PFS (HR = 0.84, 95% CI 0.58–1.20, P = .33) of HCC. Subgroup analysis further indicated that low expression of miR-122 in tumor tissues predicted poor OS in HCC patients who received curative liver resection (HR = 2.00, 95% CI 1.08–3.70, P = .03). Analysis using TCGA dataset suggested that low miR-122 expression in HCC tissues was significantly associated with OS (HR = 1.61, 95% CI 1.13–2.27, P = .008) other than PFS (HR = 1.30, 95% CI 0.96–1.75, P = .09). CONCLUSION: Low miR-122 expression in HCC tissues was a reliable indicator for predicting the OS of HCC patients who underwent curative resection. Owing to the disagreement between this meta-analysis and the TCGA dataset, the predictive value of miR-122 in tissues for PFS needs to be verified by future well-designed studies with large sample size.
format Online
Article
Text
id pubmed-6456118
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64561182019-05-29 The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset Zhang, Yanfang Li, Yongguo Jiang, Wenhui Li, Qian Lan, Yinghua Medicine (Baltimore) Research Article BACKGROUND: Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the prognosis of patients with HCC based on all eligible literatures. METHODS: Numerous electronic databases (MEDLINE, Embase, Pubmed, Google Scholar, and China Biology Medicine disc) were applied to retrieve relevant studies. Overall survival (OS) and progression-free survival (PFS) were used as primary endpoints. All statistical analyses were performed by RevMan software version 5.3.5 and STATA software version 14.1. In addition, the results of this meta-analysis were validated by an independent dataset from the Cancer Genome Atlas (TCGA). RESULTS: A total of 11 studies containing 1124 patients were included in this meta-analysis. The pooled results showed that low miR-122 expression in HCC tissues significantly associated with unfavorable OS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] 1.22–1.80, P < .001) and PFS (HR = 1.54, 95% CI 1.28–1.85, P < .001) in patients with HCC. However, the expression level of miR-122 in blood did not have the ability in predicting OS (HR = 0.75, 95% CI 0.44–1.28, P = .29) and PFS (HR = 0.84, 95% CI 0.58–1.20, P = .33) of HCC. Subgroup analysis further indicated that low expression of miR-122 in tumor tissues predicted poor OS in HCC patients who received curative liver resection (HR = 2.00, 95% CI 1.08–3.70, P = .03). Analysis using TCGA dataset suggested that low miR-122 expression in HCC tissues was significantly associated with OS (HR = 1.61, 95% CI 1.13–2.27, P = .008) other than PFS (HR = 1.30, 95% CI 0.96–1.75, P = .09). CONCLUSION: Low miR-122 expression in HCC tissues was a reliable indicator for predicting the OS of HCC patients who underwent curative resection. Owing to the disagreement between this meta-analysis and the TCGA dataset, the predictive value of miR-122 in tissues for PFS needs to be verified by future well-designed studies with large sample size. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6456118/ /pubmed/30921182 http://dx.doi.org/10.1097/MD.0000000000014810 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Zhang, Yanfang
Li, Yongguo
Jiang, Wenhui
Li, Qian
Lan, Yinghua
The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title_full The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title_fullStr The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title_full_unstemmed The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title_short The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset
title_sort clinical significance of microrna-122 in predicting the prognosis of patients with hepatocellular carcinoma: a meta-analysis validated by the cancer genome atlas dataset
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456118/
https://www.ncbi.nlm.nih.gov/pubmed/30921182
http://dx.doi.org/10.1097/MD.0000000000014810
work_keys_str_mv AT zhangyanfang theclinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT liyongguo theclinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT jiangwenhui theclinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT liqian theclinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT lanyinghua theclinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT zhangyanfang clinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT liyongguo clinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT jiangwenhui clinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT liqian clinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset
AT lanyinghua clinicalsignificanceofmicrorna122inpredictingtheprognosisofpatientswithhepatocellularcarcinomaametaanalysisvalidatedbythecancergenomeatlasdataset